Cripto-1 as a novel therapeutic target for triple negative breast cancer

• Published in: Oncotarget Vol. 6; no. 14; pp. 11910 - 11929
• Main Authors: Castro, Nadia P, Fedorova-Abrams, Natalie D, Merchant, Anand S, Rangel, Maria Cristina, Nagaoka, Tadahiro, Karasawa, Hideaki, Klauzinska, Malgorzata, Hewitt, Stephen M, Biswas, Kajal, Sharan, Shyam K, Salomon, David S
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 20.05.2015
• Subjects: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic - metabolism; Epidermal Growth Factor - metabolism; Epithelial-Mesenchymal Transition - physiology; Female; Fluorescent Antibody Technique; Gene Knockout Techniques; Immunohistochemistry; In Situ Nick-End Labeling; Laser Capture Microdissection; Mammary Neoplasms, Experimental - metabolism; Mammary Neoplasms, Experimental - pathology; Membrane Glycoproteins - metabolism; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins - metabolism; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Priority Research Paper; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; Notch4; epithelial-mesenchymal plasticity; triple-negative breast cancer; mouse model; Cripto-1

Triple-negative breast cancer (TNBC) presents the poorest prognosis among the breast cancer subtypes and no current standard therapy. Here, we performed an in-depth molecular analysis of a mouse model that establishes spontaneous lung metastasis from JygMC(A) cells. These primary tumors resembled th...